Compare ASTRAZENECA PHARMA with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SUVEN LIFESCIENCES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SUVEN LIFESCIENCES ASTRAZENECA PHARMA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 74.4 19.9 373.6% View Chart
P/BV x 21.0 4.0 519.4% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
SUVEN LIFESCIENCES
Mar-19
ASTRAZENECA PHARMA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs1,278338 378.4%   
Low Rs883169 521.0%   
Sales per share (Unadj.) Rs228.452.1 438.1%  
Earnings per share (Unadj.) Rs10.46.8 151.7%  
Cash flow per share (Unadj.) Rs16.38.6 189.7%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs98.865.3 151.3%  
Shares outstanding (eoy) m25.00127.28 19.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.9 97.2%   
Avg P/E ratio x104.237.1 280.8%  
P/CF ratio (eoy) x66.429.6 224.6%  
Price / Book Value ratio x10.93.9 281.6%  
Dividend payout %022.0 0.0%   
Avg Mkt Cap Rs m27,00832,272 83.7%   
No. of employees `0001.41.1 125.3%   
Total wages/salary Rs m1,535661 232.2%   
Avg. sales/employee Rs Th4,210.96,132.2 68.7%   
Avg. wages/employee Rs Th1,132.2611.1 185.3%   
Avg. net profit/employee Rs Th191.1803.5 23.8%   
INCOME DATA
Net Sales Rs m5,7106,635 86.1%  
Other income Rs m123242 50.6%   
Total revenues Rs m5,8336,877 84.8%   
Gross profit Rs m4631,604 28.9%  
Depreciation Rs m147221 66.6%   
Interest Rs m038 0.0%   
Profit before tax Rs m4381,587 27.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179718 24.9%   
Profit after tax Rs m259869 29.8%  
Gross profit margin %8.124.2 33.5%  
Effective tax rate %40.845.2 90.3%   
Net profit margin %4.513.1 34.6%  
BALANCE SHEET DATA
Current assets Rs m3,2096,232 51.5%   
Current liabilities Rs m2,0701,490 138.9%   
Net working cap to sales %20.071.5 27.9%  
Current ratio x1.64.2 37.1%  
Inventory Days Days7286 83.7%  
Debtors Days Days3583 42.3%  
Net fixed assets Rs m7904,043 19.5%   
Share capital Rs m50127 39.3%   
"Free" reserves Rs m2,4198,183 29.6%   
Net worth Rs m2,4698,310 29.7%   
Long term debt Rs m018 0.0%   
Total assets Rs m4,60510,389 44.3%  
Interest coverage xNM43.1-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.6 194.1%   
Return on assets %5.68.7 64.4%  
Return on equity %10.510.5 100.3%  
Return on capital %17.719.5 90.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3005,622 5.3%   
Fx outflow Rs m2,0151,799 112.0%   
Net fx Rs m-1,7153,822 -44.9%   
CASH FLOW
From Operations Rs m88356 24.7%  
From Investments Rs m-94-279 33.6%  
From Financial Activity Rs mNA-225 0.0%  
Net Cashflow Rs m-6-148 3.8%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 15.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.5 24.9%  
Shareholders   12,856 37,287 34.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 17, 2019 02:01 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS